Chardan Capital reaffirmed their buy rating on shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) in a research report released on Friday. Chardan Capital currently has a $10.00 price target on the stock.

Separately, Guggenheim reiterated a buy rating and issued a $12.00 price objective on shares of Aralez Pharmaceuticals in a report on Monday, August 15th.

Aralez Pharmaceuticals (NASDAQ:ARLZ) opened at 5.29 on Friday. The company’s market capitalization is $345.12 million. The stock’s 50 day moving average is $5.05 and its 200-day moving average is $4.16. Aralez Pharmaceuticals has a 12-month low of $3.10 and a 12-month high of $8.89.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its earnings results on Tuesday, August 9th. The company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.08. The firm had revenue of $12.60 million for the quarter, compared to analyst estimates of $9.70 million. Aralez Pharmaceuticals had a negative return on equity of 73.21% and a negative net margin of 224.35%. The business’s revenue for the quarter was up 142.3% compared to the same quarter last year. On average, equities analysts predict that Aralez Pharmaceuticals will post ($1.05) earnings per share for the current fiscal year.

In other Aralez Pharmaceuticals news, Director Robert Paul Harris sold 150,000 shares of the company’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $5.82, for a total value of $873,000.00. Following the transaction, the director now directly owns 669,094 shares in the company, valued at $3,894,127.08. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 6.77% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can bought a new position in Aralez Pharmaceuticals during the second quarter valued at approximately $100,000. Goldman Sachs Group Inc. acquired a new stake in shares of Aralez Pharmaceuticals during the first quarter worth about $109,000. Advisor Group Inc. acquired a new stake in shares of Aralez Pharmaceuticals during the second quarter worth about $118,000. Knott David M acquired a new stake in shares of Aralez Pharmaceuticals during the second quarter worth about $124,000. Finally, Alpine Partners VI LLC acquired a new stake in shares of Aralez Pharmaceuticals during the second quarter worth about $133,000. Hedge funds and other institutional investors own 49.63% of the company’s stock.

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

5 Day Chart for NASDAQ:ARLZ

Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.